MITA PET Group Announces Rebranding to Radiopharmaceutical Manufacturers and Theranostics Alliance

# MITA PET Group Rebrands to RMTA The Medical Imaging and Technology Alliance (MITA) PET Group announced on April 14, 2026, in Rosslyn, VA, that it is rebranding to the Radiopharmaceutical Manufacturers and Theranostics Alliance (RMTA). This change was stated by the MITA PET Group. RMTA is a division of the National Electrical Manufacturers Association (NEMA).

The rebranding expands the group's issue focus to include the field of theranostics. Theranostics are used for detecting serious diseases including cancers, heart disease, and Alzheimer’s. Benzinga reported the announcement details.

Legacy and Policy Focus RMTA will continue the legacy of the MITA PET Group of advancing federal policies impacting diagnostic and therapeutic radiopharmaceuticals.

The announcement occurred in Rosslyn, VA, on the current date of April 14, 2026. This continuity ensures ongoing support for policies in the radiopharmaceutical sector. The MITA PET Group, prior to rebranding, focused on these federal policies.

NEMA oversees RMTA as its division. The expansion to theranostics builds on this established work.

Expansion to Theranostics The new name, Radiopharmaceutical Manufacturers and Theranostics Alliance, reflects the inclusion of theranostics in its scope.

Theranostics involve detection methods for serious conditions such as cancers, heart disease, and Alzheimer’s. Benzinga reported this expansion in issue focus. This shift broadens the alliance's engagement beyond prior PET-specific efforts.

The rebranding announcement was made directly by the MITA PET Group. RMTA maintains its position within NEMA.

Organizational Structure As a division of the National Electrical Manufacturers Association (NEMA), RMTA operates under this established framework.

The legacy of advancing federal policies on radiopharmaceuticals persists under the new name. The event took place in Rosslyn, VA, on April 14, 2026. Benzinga reported the rebranding and its implications for policy advancement.

Theranostics' role in disease detection, including cancers, heart disease, and Alzheimer’s, aligns with the expanded focus. No further changes to structure were detailed in the announcement.